Curosurf surfactant application on preterm babies with respiratory complications-health-economic benefits
- PMID: 38962356
- PMCID: PMC11217823
- DOI: 10.4314/ahs.v24i1.27
Curosurf surfactant application on preterm babies with respiratory complications-health-economic benefits
Abstract
Background: The implementation of surfactant for respiratory syndrome approbates the therapy as a revolutionary method in intensive neonatal therapy and respiratory resuscitation. It is important to investigate the costs of this treatment.
Objective: The aim of the study is to analyze the data by the application of the surfactant Curosurf to preterm babies with respiratory complications and describe the treatment costs, healthcare resource utilization and evaluate economic benefits of surfactant use in the treatment of neonates with respiratory distress syndrome (RDS) and hyaline-membrane disease (HDM).
Methods: A retrospective survey was performed covering 167 babies based on respiratory complications due to preterm birth and the necessity to apply a surfactant therapy. A documentary method was implemented and for each patient, an individual research protocol was filled out - a questionnaire created specifically for the purposes of the study.
Results and discussion: An analysis of the data from the application of CUROSURF was made and the obtained therapeutic results were compared to expenditures for the therapy, short-term therapeutic effect, benefits and consequences of the therapy of preterm newborns with respiratory complications. The application of CUROSURF to babies with RDS resulted in the realization of net savings due to the elimination of the necessity of conducting several diagnostic and therapeutic procedures as well as their duration reduction of hospital stay, thus defining its health-economic benefits.
Conclusions: The models of evaluation of cost effectiveness reveal that the medicinal product is expensive but effective from the aspect of short-term therapeutic results.
Keywords: CUROSURF; health-economic benefits; preterm babies; respiratory complications; surfactant.
© 2024 Mihaylova A et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures
Similar articles
-
Comparison of the Effectiveness of Beraksurf and Curosurf Exogenous Surfactants in the Treatment of Respiratory Distress Syndrome in Preterm Neonates: A Double-blind Randomized Study in the West of Iran.Curr Pediatr Rev. 2025;21(2):200-206. doi: 10.2174/0115733963271143240403070529. Curr Pediatr Rev. 2025. PMID: 38629362 Clinical Trial.
-
Analysis of the cost-effectiveness of surfactant treatment (Curosurf®) in respiratory distress syndrome therapy in preterm infants: early treatment compared to late treatment.Ital J Pediatr. 2014 May 2;40:40. doi: 10.1186/1824-7288-40-40. Ital J Pediatr. 2014. PMID: 24886906 Free PMC article. Clinical Trial.
-
Cost effectiveness of surfactant replacement in preterm babies.Pharmacoeconomics. 1993 May;3(5):362-73. doi: 10.2165/00019053-199303050-00004. Pharmacoeconomics. 1993. PMID: 10146887 Review.
-
Characterization of atomization and delivery efficiency of exogenous surfactant in preterm infant lungs using an ex vivo respiratory model.Sci Rep. 2025 May 29;15(1):18942. doi: 10.1038/s41598-025-03199-x. Sci Rep. 2025. PMID: 40442153 Free PMC article.
-
A unique story in neonatal research: the development of a porcine surfactant.Neonatology. 2015;107(4):321-9. doi: 10.1159/000381117. Epub 2015 Jun 5. Neonatology. 2015. PMID: 26044099 Review.
References
-
- Sandeva M, Uchikova E. Frequency and medical-social aspects of preterm birth. Obstetrics and gynecology. 2016;2:27–33. - PubMed
-
- Fox G, Sothinathan U. The choice of surfactant for treatment of respiratory distress syndrome in preterm infants: A review of the evidence. Respiratory Therapy. 2005;1(1):8–12.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical